Approved for use through 04/30/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449/PTO		_	Complete if Known		
				Application Number	10/583,056	
IN.	IFORMATION	I DI	SCLOSURE	Filing Date	March 16, 2007	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Katherine S. Bowdish	
				Art Unit	1644	
	(Use as many sheets as necessary)			Examiner Name	G. R. Ewoldt	
Sheet	cheet 1 of 4		Attorney Docket Number	ALEX-P01-112		

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AD*	US-6,605,279-B2	08-12-2003	Freeman et al.		
	AE*	US-20030134297	07-17-2003	Olson et al.		
	AF*	US-6,548,275	04-15-2003	Goldenberg		
	AG*	US-7,285,642	10-06-2005	Figdor et al.		

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear		
	ВН	WO-95/032734	12-07-1995	Innogenetics NV			
	ВІ	WO-00/63251	10-26-2000	Univ Nijmegen et al.			
	ВЈ	WO-02/50119	06-27-2002	Stichting Katholieke Universiteit			
						П	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (03-09)
Approved for use through 04/30/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/583,056	
II.	IFORMATION	1 DI	SCLOSURE	Filing Date	March 16, 2007	
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Katherine S. Bowdish	
				Art Unit	1644	
	(Use as many sheets as necessary)			Examiner Name	G. R. Ewoldt	
Sheet	Sheet 2 of 4		Attorney Docket Number	ALEX-P01-112		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CC1	Purified Mouse Anti-Human Monoclonal Antibody, BD PharMingen Technical Data Sheet, BD Biosciences Product Information sheet, Catalog Number 551186, 05/01/01.	
	CD1	Amersdorfer et al., Molecular Characterization of Murine Humoral Immune Response to Botulinum Neurotoxin Type A Binding Domain as Assessed by Using Phage Antibody Libraries. Infection and Immunity, 65, pp. 3743-3752 (1997)	
	CE1	Ahsan et al., Immunopathogenesis of Human Immunodeficiency Virus. Seminars in Nephrology, Vol. 18, No. 4, pages 422-435 (1998)	
	CF1	Berkower, I., et al., "CHIMERIC HIV-1 ENVELOPE GP120-HEPATITIS B CORE ANTIGEN (HbcAg) FUSION PROTEINS FOR HIV-1 VACCINES," FASEB Journal, 10(6):A1082 (1996).	
	CG1	Eck J., et al., "Cloning of the Mistletoe Lectin Gene and Characterization of the Recombinant A-Chain," European Journal of Biochemistry, 264:775-784 (1999).	
	CH1	FDA Approves Second Indication for Monolclonal Antibody, June 28, 1993, printed on November 12, 2004 from http://www.fda.gov/bbs/topics/ANSWERS/ANS00506.html, June 28, 1993.	
	CI1	Fè d'Ostiani, C., et al., "Dendritic Cells Discriminate between Yeasts and Hyphae of the Fungus Candida albicans: Implications for Initiation of T Helper Cell Immunity In Vitro and In Vivo," J. Exp. Med., 191(10):1661-1673 (2000).	
	CJ1	Forsyth, C. B., et al., "Interaction of the Fungal Pathogen Candida albicans with Integrin CD11b/CD18: Recognition by the I Domain Is Modulated by the Lectin-Like Domain and the CD18 Subunit," The Journal of Immunology, 161:6198-6205 (1998).	
	CK1	Fumero et al., Immunosuppressive drugs as an adjuvant to HIV treatment. Journal of Antimicrobial Chemotherapy Vol. 53, pages 415-417 (2004)	
	CL1	Harlow and Lane, Antibodies, A Laboratory Manual. 1988 Cold Spring Harbor Laboratory, pages 141-142	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (03-09)
Approved for use through 04/30/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	Substitute for form 1449/PTO INFORMATION DISCLOSURE	ı	Complete if Known		
				Application Number	10/583,056
11	NFORMATION	I DI	SCLOSURE	Filing Date	March 16, 2007
8	STATEMENT E	3Y /	APPLICANT	First Named Inventor	Katherine S. Bowdish
				Art Unit	1644
	(Use as many she	eets as	s necessary)	Examiner Name	G. R. Ewoldt
Sheet	Sheet 3 of 4		Attorney Docket Number	ALEX-P01-112	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CM1	Kataoka et al., Cancer Research, 38(5), pp. 1202-1207 (1978) - Abstract only from Biosis database.	
	CN1	Marth, T., et al., "Regulation of Interleukin-12 by Complement Receptor 3 Signaling," The Journal of Experimental Medicine, 185(11):1987-1995 (1997).	
	CO1	Murdoch et al., Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Research and Therapy 4:9 (2007)	
	CP1	Netea, M. G., et al., "Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors," The Journal of Clinical Investigation, 116(6):1642-1650 (2006).	
	CQ1	Package insert for Orthoclone OKT3 Sterile Solution (murumonab-CD3) from Ortho Biotech Products LP, Raritan, NJ, Revised March 2001.	
	CR1	Product Information for Affinity Purified anti-human CD209 (DC-SIGN) antibody, from eBioscience, printed on January 5, 2004 from http://www.ebioscience.com/ebioscience/specs/antibody_14/14-2099.htm	
	CS1	Rosati et al., Cytokine Response to Inactivated Candida albicans in Mice. Cell. Immunol., 162:256-264 (1995)	
	CT1	Sequence Alignment of Curtis et al., PNAS 89: 8356-8360 (1992) with SEQ ID NO: 2 from U.S.S.N. 09/719,961.	
	CU1	Stephen Smith. The patogenesis of HIV infection: stupid may not be so dumb after all. Retrovirology 3:60 (2006)	
	CV1	Steinbrook, R., "One Step Forward, Two Steps Back - Will There Ever Be an AIDS Vaccine?," N. Engl. J. Med., 357:2653-2655 (2007).	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (03-09)
Approved for use through 04/30/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Complete if Known			
				Application Number	10/583,056
11	NFORMATION	I DI	SCLOSURE	Filing Date	March 16, 2007
l s	STATEMENT E	3Y /	APPLICANT	First Named Inventor	Katherine S. Bowdish
				Art Unit	1644
	(Use as many she	eets as	s necessary)	Examiner Name	G. R. Ewoldt
Sheet	Sheet 4 of 4		Attorney Docket Number	ALEX-P01-112	

	Include name of the author (in CARITAL LETTERS), title of the article (when appropriets), title of	
Cite No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CW1	Szabo, I., et al., "Modulation of Macrophage Phagocytic Activity by Cell Wall Components of Candida albicans," Cellular Immunology, 164:182-188 (1995).	
CX1	Taken, P.J., et al., "Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody," Blood, 106(4):1278-1285 (2005).	
CY1	Vakeva, Antti, P., et al., "Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion," Circulation, 97, pp. 2259-2267 (1998).	
CZ1	Woodle, E.S., et al., Phase 1 Trial of Humanized, Fe Receptor Nonbinding OKT3 Antibody, huOKT3γ1(Ala-Ala) In the Treatment of Acute Renal Allograft Rejection. Translplantation, 68, pp. 608-616 (1999).	
CA2	Yan et al., "b-Glucan, a "Specific" Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18)," The Journal of Immunology, 163(6):3045-3052 (1999).	
	CW1 CX1 CY1 CZ1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. CW1 Szabo, I., et al., "Modulation of Macrophage Phagocytic Activity by Cell Wall Components of Candida albicans," Cellular Immunology, 164:182-188 (1995). Taken, P.J., et al., "Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody," Blood, 106(4):1278-1285 (2005). CY1 Vakeva, Antti, P., et al., "Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion," Circulation, 97, pp. 2259-2267 (1998). Woodle, E.S., et al., Phase 1 Trial of Humanized, Fe Receptor Nonbinding OKT3 Antibody, huOKT3γ1(Ala-Ala) In the Treatment of Acute Renal Allograft Rejection. Translplantation, 68, pp. 608-616 (1999). Yan et al., "b-Glucan, a "Specific" Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.